Comparative Pharmacology
Head-to-head clinical analysis: ENOXAPARIN SODIUM PRESERVATIVE FREE versus LOVENOX PRESERVATIVE FREE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENOXAPARIN SODIUM PRESERVATIVE FREE versus LOVENOX PRESERVATIVE FREE.
ENOXAPARIN SODIUM (PRESERVATIVE FREE) vs LOVENOX (PRESERVATIVE FREE)
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Enoxaparin binds to antithrombin III (ATIII), accelerating its inhibition of coagulation factors Xa and IIa (thrombin). Its anti-factor Xa to anti-factor IIa activity ratio is approximately 3.6:1.
Low molecular weight heparin (LMWH) that potentiates antithrombin III, accelerating inactivation of factor Xa and thrombin.
1 mg/kg subcutaneously every 12 hours or 1.5 mg/kg subcutaneously once daily. For prophylaxis: 40 mg subcutaneously once daily or 30 mg subcutaneously every 12 hours.
1 mg/kg subcutaneously every 12 hours or 1.5 mg/kg subcutaneously once daily.
None Documented
None Documented
Terminal elimination half-life is 4.5 hours after subcutaneous administration based on anti-Factor Xa activity; prolonged to 6-7 hours in renal impairment (CrCl <30 mL/min).
Terminal half-life: 3-5 hours after subcutaneous injection; prolonged in renal impairment (up to 8-10 hours with CrCl <30 mL/min).
Renal excretion of anti-Factor Xa activity accounts for approximately 40% of total clearance; a small fraction undergoes biliary/fecal elimination (<10%).
Renal: 40-60% as unchanged drug and low molecular weight fragments via glomerular filtration; biliary/fecal: negligible.
Category A/B
Category C
Low Molecular Weight Heparin
Low Molecular Weight Heparin